A randomised phase II study evaluating cediranib versus cediranib and saracatanib in patients with relapsed metastatic clear cell renal cancer.
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Cediranib (Primary) ; Saracatinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms COSAK
- 06 Jun 2017 Results of retrospective analysis assessing dynamic changes in prognostic marker to predict survival presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 22 Jan 2016 Results published in the Annals of Oncology
- 31 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ISRCTN.